Search
New MSK research discovers a new approach that could prevent chemotherapy-related leukemia; shows how monoclonal antibodies can turn neutrophils into cancer killers; helps develop sensitive CAR T cells that target CD70 antigen to destroy cancer cells; and uses single-cell studies to yield new clues about a rare, aggressive pediatric sarcoma.
The initial results of an ongoing study show that a liquid biopsy has advantages over a tissue biopsy for people with lung cancer.
Maria Jasin’s discoveries have led to concrete advances in patient care. The targeted medicines called PARP inhibitors, for example, are based on knowledge gained from her work.
MSK researchers presented practice-changing advances in new treatment approaches for a range of cancer types at the 2025 ASCO Annual Meeting.Highlights included breakthroughs for patients with advanced gastric cancer, lung cancer, Lynch syndrome-related cancer and salivary gland cancer. Additionally, the first-ever CAR T cell trial for patients with light chain amyloidosis is showing promising results.
Dimiter Tassev, a member of Gerstner Sloan Kettering's inaugural class, has completed all his degree requirements and will receive his PhD in May.
Foundation Medicine and Memorial Sloan Kettering Cancer Center today announced a partnership that brings together clinical, genomic and computational expertise to advance patient care in hematologic cancers.
Annually, Gerstner Sloan Kettering recognizes student research through fellowship awards with the Grayer Fellowships, the Catell Fellowship, the Olayan Fellowship, the Palestin Fellowship, and the Geoffrey Beene Graduate Student Fellowship.
New MSK research shows the Make-an-IMPACT program improves global access to genomic testing in pediatric cancer patients; helped develop an experimental antibody that shows promise against metastatic cancer; sheds light on the origins of ERG-driven prostate cancer; and finds Dupilumab is a successful agent to treat skin toxicities related to antibody-drug conjugates.
MSK’s Kathryn Beal presents new findings on combining radiation with immunotherapy for brain cancer.
Resection of all residual disease after salvage chemotherapy offers the best chance for a cure for patients with refractory or relapsed advanced testicular cancer, according to the results of our recent retrospective study.